Background Ovarian cancer continues to have a poor prognosis with the majority of women
diagnosed with advanced disease. Therefore, we undertook the UK Collaborative Trial of …

Objective There is a need to develop and validate biomarkers for treatment response and
survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response …

The discovery of genes underlying inherited predisposition to breast and ovarian cancer has
revolutionized the ability to identify women at high risk for these diseases before they …

Background The increase in the worldwide incidence of endometrial cancer relates to rising
obesity, falling fertility, and the ageing of the population. Transvaginal ultrasound (TVS) is a …

Population genomic screening to detect carriers of rare monogenic variants for medically
actionable conditions is supported by substantial evidence of clinical utility and cost …

Background: Technological advances raise the possibility of systematic population-based
genetic testing for cancer-predisposing mutations, but it is uncertain whether benefits …

Purpose There are no internationally agreed upon clinical guidelines as to which women
with gynecological cancer would benefit from Lynch syndrome screening or how best to …

Background: Population-based testing for BRCA1/2 mutations detects the high proportion of
carriers not identified by cancer family history (FH)–based testing. We compared the cost …

Background The cost-effectiveness of population-based panel testing for high-and moderate-
penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We …

For the randomized general population, the United Kingdom Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS) investigated a new multimodal screening test using the Risk …